BURLINGTON, Mass. _ Dyax Corp. on Tuesday reported a loss of $2.3 million in its fourth quarter. The average estimate of analysts surveyed by Zacks Investment Research was for a loss of 4 cents per share. Dyax shares have climbed 17 percent since the beginning of the year.
Check out which companies are making headlines after the bell Thursday: BofA, Micron, Global Payments
Check out which companies are making headlines after the bell Thursday:
Starbucks, Tribune, Nastech! Buy or sell? Cramer's got you covered.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Dyax said its product candidate for hereditary angioedema, a genetic disease, met its main goal in a late-stage trial, sending the biopharmaceutical company's shares up more than 40% in after-hours trading.